CD274 and neoplasm: ICIs, such as cytotoxic T-lymphocyte antigen-4, programmed cell death protein-1 (PD-1), and its ligand PD-L1, target down-regulators of the anticancer immune response, unleashing the host immune reaction against tumor cells by T-cell activation.